| Execution period | FY 2026-27 |
|---|
BSE filing, NSE: AJANTPHARM. Summary written from the filing by ALFA Finder's alert engine.
Ajanta Pharma Ltd: key numbers
- Share price
- ₹3,508.80
- Market cap
- ₹43,846 Cr
- Revenue (annual)
- ₹5,453 Cr
- Net profit (annual)
- ₹1,056 Cr
- P/E (TTM)
- 34.7×Sector 45.9×
- Promoter holding
- 63.47%-0.01% QoQ
- FII holding
- 7.62%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ajanta Pharma Ltd
All →Ajanta Pharma Earnings Call Transcript: Key Takeaways
Ajanta Pharma posted robust revenue and PAT growth, primarily driven by a temporary US market upside. Management remains cautious as competition intensifies.
- Call
- Guides 18% growth
Ajanta Pharma Q2 FY27 Results: Net Profit ₹388.1 Cr, Up 49.2% YoY
Ajanta Pharma Ltd reported revenue from operations of ₹1,794 Cr (+32.5% YoY) and net profit of ₹388.1 Cr (+49.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹388.1 Cr · +49.2% YoY
Ajanta Pharma Share Pledge
Ajanta Pharma promoter Aayush Agrawal (trustee) created a pledge on 30,000 equity shares. The pledge was made as a top-up call due to share price reduction.
Ajanta Pharma Board Meeting Date
Ajanta Pharma has scheduled a Board meeting for 30 October 2026 to consider Q2/H1 2026 unaudited financial results. No material decision has been taken yet.
Ajanta Pharma Other Announcement
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Ajanta Pharma Share Pledge
Promoter Aayush Agrawal Trust created pledge on 4,60,000 Ajanta Pharma shares. The pledge secures an NCD issue in favor of CTL Trusteeship Ltd.
Other board meeting outcome announcements
All →VCU Data Management Board Meeting Outcome
VCU Data Management appointed M/s. Utkarsh Shah & Co. as Secretarial Auditors for five years from FY 2026-27, subject to AGM approval. No monetary amount is disclosed, so this is an auditor appointment intimation.
- Execution
- FY 2026-27 to 2030-31 (five years)
Hardcastle & Waud Manufacturing Company Board Meeting Outcome
The board revoked its earlier Mumbai office shift and approved moving the registered office to Mira Road, Thane. The change awaits shareholder and regulatory approval.
Greenply Industries Board Meeting Outcome
Greenply appoints MSKA & Associates LLP as statutory auditor for five years from the 2027 AGM, subject to shareholder approval. Incumbent BSR & Co. continues until then.
- Execution
- 5 years, from the conclusion of the 37th AGM (2027) to the conclusion of the 42nd AGM (2032)
Greaves Cotton Board Meeting Outcome
Greaves Cotton confirmed its Board met on October 29, 2026, on unaudited half-year results. No new financial figures are disclosed in this filing.
Popular Vehicles and Services Board Meeting Outcome
Popular Vehicles passed a circular resolution approving a routine AOA amendment on the common seal. A postal ballot notice and scrutinizer were also appointed.
R R Kabel Board Meeting Outcome
RR Kabel's board approved amendments to its UPSI fair disclosure code on 28 October 2026. The amended code is enclosed and posted on the company website.